Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271617 · ClinicalTrials.gov registry record
VIDAS Nephroclear (NCL) CCL14 - Sample Stability
A clinical trial, sponsored by BioMérieux.
- Completed
- Registry status
- 40
- Enrollment target
NCT05271617: Completed study, sponsored by BioMérieux.
NCT05271617 is a clinical trial that has completed, run by BioMérieux. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05271617 has completed, sponsored by BioMérieux.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This VIDAS® NEPHROCLEAR™ CCL14 (VIDAS® NCL™ CCL14) Sample Stability clinical trial is a multicenter, prospective, and qualitative study. The main study objective is to determine sample stability conditions for the VIDAS® NEPHROCLEAR™ CCL14 Test. This test is intended to be used in conjunction with clinical evaluation in ICU patients with moderate to severe (stage 2 or 3) acute kidney injury (AKI) as an aid in the risk assessment for developing persistent severe AKI (stage 3 AKI lasting ≥ 72 hours) within 48 hours of patient assessment. The VIDAS® NEPHROCLEAR™ CCL14 Test is intended to be used in patients 21 years of age or older.
Primary Outcome
Detection of CCL14 levels in urine, spanning the measuring range of the assay for several sample conditions.
Interventions
- DIAGNOSTIC_TEST VIDAS® NEPHROCLEAR™ CCL14
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2023-07-31 |
What the finished NCT05271617 record still lists
NCT05271617 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which VIDAS® NEPHROCLEAR™ CCL14 is the first listed.
NCT05271617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05271617 about?
NCT05271617 is a clinical study titled "VIDAS Nephroclear (NCL) CCL14 - Sample Stability". This VIDAS® NEPHROCLEAR™ CCL14 (VIDAS® NCL™ CCL14) Sample Stability clinical trial is a multicenter, prospective, and qualitative study. The main study objective is to determine sample stability conditions for the VIDAS® NEPHROCLEAR™ CCL14 Test. This test is intended to be used in conjunction with c...
What is the current status of trial NCT05271617?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2022-03-10. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT05271617?
The interventions under investigation include: VIDAS® NEPHROCLEAR™ CCL14 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05271617?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI